Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
49,625,327
-
Number of holders
-
22
-
Total 13F shares, excl. options
-
6,080,809
-
Shares change
-
-265,373
-
Total reported value, excl. options
-
$19,096,287
-
Value change
-
-$834,398
-
Number of buys
-
8
-
Number of sells
-
-5
-
Price
-
$3.14
Significant Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) as of Q3 2022
24 filings reported holding CADL - Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q3 2022.
Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) has 22 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6,080,809 shares
of 49,625,327 outstanding shares and own 12% of the company stock.
Largest 10 shareholders include Northpond Ventures, LLC (1,935,215 shares), FRANKLIN RESOURCES INC (1,125,000 shares), FMR LLC (899,399 shares), Sands Capital Ventures, LLC (811,737 shares), VANGUARD GROUP INC (405,461 shares), Point72 Asset Management, L.P. (403,131 shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (132,700 shares), GEODE CAPITAL MANAGEMENT, LLC (128,846 shares), BlackRock Inc. (124,970 shares), and STATE STREET CORP (27,600 shares).
This table shows the top 22 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.